Final Overall Survival, Safety, and Quality of Life Results From a Phase 2 Study of Crizotinib in East Asian Patients With ROS1-Positive Advanced NSCLC-Reference-Cited by-同舟云学术

Final Overall Survival, Safety, and Quality of Life Results From a Phase 2 Study of Crizotinib in East Asian Patients With ROS1-Positive Advanced NSCLC

Published:2022-10 Issue:10 Volume:3 Page:100406
ISSN:2666-3643
Container-title:JTO Clinical and Research Reports
language:en
Short-container-title:JTO Clinical and Research Reports

Author:

Wu Yi-Long^ORCID,Lu Shun,Yang James Chih-Hsin,Zhou Jianying,Seto Takashi,Ahn Myung-Ju,Su Wu-Chou,Yamamoto Noboru,Kim Dong-Wan,Paolini Jolanda,Usari Tiziana,Iadeluca Laura,Wilner Keith D.,Goto Koichi

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine,Oncology

Reference31 articles.

1. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib;Lynch;N Engl J Med,2004

2. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer;Soda;Nature,2007

3. Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer;Rikova;Cell,2007

4. Molecular pathways: ROS1 fusion proteins in cancer;Davies;Clin Cancer Res,2013

5. World Health Organization, International Agency for Research on Cancer. Globocan 2020: lung cancer. http://gco.iarc.fr/today/data/factsheets/cancers/15-Lung-fact-sheet.pdf. Accessed June 14 2021.

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy and safety of crizotinib in the treatment of advanced non-small cell lung cancer with ROS1 gene fusion: a systematic literature review and meta-analysis of real-world evidence;Lung Cancer;2024-06

2. Overall survival and central nervous system activity of crizotinib in ROS1-rearranged lung cancer—final results of the EUCROSS trial;ESMO Open;2024-02

3. Comprehensive Review of ROS1 Tyrosine Kinase Inhibitors-Classified by Structural Designs and Mutation Spectrum (Solvent Front Mutation [G2032R] and Central β-Sheet 6 [Cβ6] Mutation [L2086F]);Journal of Thoracic Oncology;2023-12

4. Anaplastic Lymphoma Kinase Inhibitor-Induced Neutropenia: A Systematic Review;Cancers;2023-10-11

5. ROS1 as a possible prognostic biomarker of cervical adenocarcinoma: An exploratory analysis with next-generation sequencing;Gynecologic Oncology;2023-04